On June 22, at the EHA22 National Societies Dinner in Madrid, broad support from national society representatives was expressed for the Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive. Drafted by EHA and co-signed by the hematology societies of the 28 EU Member States, the declaration calls for increasing the minimum length of hematology training and for harmonization of training requirements across Europe.
June 22, 2017, Madrid – The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.
HemaSphere is an open access journal dedicated to support hematology patient care, research and education worldwide. EHA’s new journal intends to publish results of highly relevant basic, translational and clinical research in hematology. In addition to original research, it will also publish review and guideline articles, as well as insightful discussions of research and hematology news.
HemaSphere will be under the editorial leadership of Co-Editors-in-Chief, Dr Andreas Engert of University of Cologne and Dr Jan Cools of KU Leuven. “HemaSphere will be your new forum to publish your best research and to get updated on new developments in the hematology field,” according to Dr Cools. “It will not be just another ‘bloody’ journal. It is a new and different open access journal, with an innovative review process leading to rapid publication and with insightful discussions and summaries of new developments in the hematology field,” he added.
More than 10,000 hematology professionals from around the world will gather and discuss the latest developments in hematology research and clinical practice. The 22nd Congress of the European Hematology Association at the Feria de Madrid (IFEMA), Madrid, Spain will be home to these discoveries, a selection of which will be presented to the media.
8 June, Brussels: The Brussels-based European Alliance for Personalised Medicine (EAPM) will once again be taking part in a major event in the Spanish capital of Madrid, this time on 22 June.
The prestigious annual EHA Congress, which brings together Europe’s haematology community, will feature an EAPM roundtable as part of its events schedule.
Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4 in Barcelona, Spain.
Delegates from the Middle East, Africa, Asia and Europe gathered in Dubai in November 2016 to learn about the latest updates in hematology and network with their peers during the three-day Highlights of Past EHA (HOPE).
[Vilnius, March 10, 2017] Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States.
At the third conference on European Reference Networks (ERNs) yesterday in Vilnius, Lithuania, EuroBloodNet was officially awarded as one of the recently approved ERNs.
Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies.
Salamanca, January 19, 2017. Attended by 150 participants from 18 countries the HARMONY project successfully kicked off with a two-day meeting on January 16 and 17.
HARMONY is a European Network of Excellence that captures, integrates, analyses and seeks to harmonize Big Data on various hematological malignancies. The Big Data platform that will be developed is foreseen to enable the rapid definition of promising treatment strategies for individual patients.
EHA is entering the next phase of its Hematology Awareness Campaign this fall. Face-to-face meetings will be conducted with EU institutions and other relevant stakeholders in Brussels, to raise awareness in hematology, increase the visibility of EHA, advocate key EHA positions, contribute to important policy debates and build relationships and alliances.